|Bid||0.00 x 2900|
|Ask||0.00 x 1300|
|Day's range||7.09 - 7.42|
|52-week range||4.31 - 9.48|
|PE ratio (TTM)||N/A|
|Earnings date||5 Nov 2018 - 9 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.00|
Assertio Therapeutics, Inc. (NASDAQ:ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “ASRT” and a new CUSIP number, 04545L 107, at the opening of trading today, August 15, 2018. “Over the last several years, we have taken strategic actions to transition the Company to focus on our neurology, orphan and specialty medicines,” said Arthur Higgins, President and CEO of Assertio Therapeutics, Inc. “As we’ve transformed, it has become clear that the name Depomed no longer accurately reflects the business we’re in today or the future direction in which we’re headed.
The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...
--Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise--. --Confirms Regulatory Plan to File for FDA Approval of Cosyntropin ...
NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar ...
NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Facebook, ...
Inc. and Purdue Pharma LP are trying to resolve a patent dispute involving Purdue’s painkiller OxyContin. The companies didn’t disclose terms of the settlement talks Monday, but Janney Montgomery Scott’s Ken Trbovich said a settlement could “easily support the lower end” of his April 2016 forecast of potential royalties for Depomed of $3 to $8 a share on an estimated $10 billion in cumulative OxyContin sales. By Mr. Trbovich’s estimate, Depomed could bring in about $190 million, or about one-third of its market value as of Monday’s closing, which reflected a 19% surge on news of the settlement discussions.
LAKE FOREST, Ill., July 09, 2018-- Depomed, Inc. today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, ...
Depomed, Inc. (DEPO) announced that effective July 3, 2018, the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”). The RSUs were granted as inducements material to each such individual’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4). The RSUs are subject to such employee’s continued service relationship with the Company, the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted. Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need.
The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...
President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.